Zura Bio (ZURA) AI Stock Analysis

• Market Cap: $134.59M
• Dividend Yield: N/A
• Average Volume (3M): 348.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: N/A
• EPS Growth: -50.20%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.17
• Shares Outstanding: 65,018,060
• 10 Day Avg. Volume: 325,053
• 30 Day Avg. Volume: 348,746
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.31
• Enterprise Value/Revenue: -21.14K
• Enterprise Value/Gross Profit: 1.92K
• Enterprise Value/Ebitda: 0.60
• 1Y Price Target: $9.67
• Price Target Upside: 339.55% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 43 Neutral
• Price Target: ―

Zura Bio's overall stock score is driven by significant financial challenges, including no revenue generation and consistent losses despite a strong cash position and no debt. While technical indicators suggest some short-term bullish trends, the negative P/E ratio and lack of dividends underscore the valuation concerns. The company's ability to generate revenue and improve operational efficiency will be crucial for future performance.

Positive Factors

Clinical Trials

Ph 2 studies for lead asset tibulizumab (IL17A / BAFF bispecific) remain on track in systemic sclerosis (SSc) and hidradenitis suppurativa (HS) with data expected 2H26.

Drug Efficacy

The dual-mechanism of ZURA's tibulizumab in HS is believed to offer a solid chance to improve on current and emerging standards of care.

Market Competitiveness

The efficacy of IL-17 is well-validated, and a better-optimized IL-17A may improve on existing benchmarks.

Negative Factors

Clinical Data Concerns

The initiation of the Phase 2 study for tibulizumab in hidradenitis suppurativa raises questions due to past lackluster clinical data and no clear dose-dependent response.

Financial Outlook

Financial results reported show a reduction in cash and cash equivalents and an increase in potentially dilutive shares outstanding, leading to a reduced 12-month price target.

Market Competition

The market for HS treatment is increasingly competitive, with dual IL-17A/F inhibitors showing impressive efficacy and setting a high benchmark that could overshadow older treatments like tibulizumab.

Zura Bio Business Overview & Revenue Model

Company Description

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

How the Company Makes Money

Zura Bio generates revenue through the development and commercialization of its proprietary drug candidates. The company's primary revenue streams include licensing agreements, partnerships with other pharmaceutical companies, and potential sales of successfully developed therapies. Zura Bio collaborates with strategic partners for clinical development, regulatory approval, and distribution of its products, which can result in milestone payments and royalties. Additionally, the company may engage in research and development collaborations that provide funding and resource sharing to advance its product pipeline.

Zura Bio Financial Statement Overview

Summary

Zura Bio is facing financial difficulties with no revenue generation and increasing losses. The strong cash position and absence of debt are positives, providing financial stability in the short term. However, the company must address its operational inefficiencies and explore revenue generation strategies to ensure long-term viability. The current trajectory is unsustainable without a shift in operational or strategic direction.

Income Statement

Zura Bio has consistently reported zero revenue over the past three years, with increasing net losses. This reflects a challenging financial position in terms of generating income. The negative EBIT and EBITDA margins further highlight inefficiencies in cost management or lack of operational revenues.

Balance Sheet

The balance sheet shows a strong cash position with no debt, which provides a buffer against operational losses. The company's equity has significantly improved over the years, moving from negative to positive, indicating some financial recovery. However, the lack of revenue generation is a concern despite the strong cash reserves.

Cash Flow

Operating cash flow remains negative, reflecting ongoing operational challenges. The free cash flow is also negative, indicating that the company is not generating enough cash to cover its capital expenditures. While financing cash flow is positive, suggesting successful fundraising efforts, reliance on external financing could be risky without revenue improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.00K	0.00	0.00	0.00	0.00
Gross Profit	-22.00K	-9.00K	0.00	0.00	0.00
EBITDA	-70.24M	-52.39M	-60.56M	-27.33M	8.42M
Net Income	-67.76M	-45.39M	-60.36M	3.55M	8.42M
Balance Sheet
Total Assets	157.81M	179.53M	100.84M	141.51M	4.72M
Cash, Cash Equivalents and Short-Term Investments	154.49M	176.50M	99.81M	13.79K	4.72M
Total Debt	0.00	0.00	0.00	355.60K	0.00
Total Liabilities	18.70M	19.51M	21.29M	14.82M	39.00K
Stockholders Equity	125.91M	146.81M	59.33M	-32.06M	4.68M
Cash Flow
Free Cash Flow	-43.69M	-28.15M	-23.05M	-13.07M	-1.10M
Operating Cash Flow	-43.57M	-28.08M	-15.05M	-1.07M	-1.10M
Investing Cash Flow	-122.00K	-5.08M	-8.00M	-12.00M	-139.38M
Financing Cash Flow	9.74M	109.84M	121.29M	355.60K	141.21M

Zura Bio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZURA, the sentiment is Positive. The current price of 2.2 is above the 20-day moving average (MA) of 1.86, above the 50-day MA of 1.59, and above the 200-day MA of 1.64, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 71.18 is Negative, neither overbought nor oversold. The STOCH value of 66.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZURA.

Zura Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRBU	52 Neutral	$172.28M	―	-68.93%	―	-72.45%	-28.60%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
ANIX	49 Neutral	$95.67M	―	-61.14%	―	―	-2.11%
ZURA	43 Neutral	$134.59M	―	-46.33%	―	―	-50.20%
ATOS	36 Underperform	$99.62M	―	-41.66%	―	―	-8.91%
HLVX	35 Underperform	$105.30M	―	-40.31%	―	―	57.64%
ELTX	30 Underperform	$177.27M	―	-9999.00%	―	―	-4.60%

Zura Bio Corporate Events

Zura Bio to Participate in Global Healthcare Conference

On February 24, 2025, Zura Bio announced its participation in the Leerink Partners Global Healthcare Conference scheduled for March 11, 2025. The company’s senior leadership will engage in a fireside chat and host investor meetings, reflecting its proactive approach to engaging with stakeholders and potentially enhancing its market visibility.